Special Issue "Human Serum Albumin: From Molecular Aspects to Biotechnological Applications"
Deadline for manuscript submissions: closed (31 July 2021).
Human serum albumin (HSA), the most abundant protein in plasma, is a monomeric multidomain macromolecule, the main determinant of plasma oncotic pressure, and the main modulator of fluid distribution between body compartments. HSA displays an extraordinary ligand-binding capacity, providing a depot and carrier for many endogenous and exogenous compounds. Indeed, HSA serves as the main carrier for fatty acids, affects the pharmacokinetics of many drugs, provides the metabolic modification of some ligands, renders potential toxins harmless, accounts for most of the anti-oxidant capacity of human plasma, and displays (pseudo-)enzymatic properties. Recent evidence also supports a role of HSA in human innate immunity. HSA is a valuable biomarker of many diseases, including cancer, rheumatoid arthritis, ischemia, post-menopausal obesity, severe acute graft-versus-host disease, and diseases that need monitoring of glycemic control. Moreover, HSA is widely used clinically to treat several diseases, including hypovolemia, shock, burns, surgical blood loss, trauma, hemorrhage, cardiopulmonary bypass, acute respiratory distress syndrome, hemodialysis, acute liver failure, chronic liver disease, nutrition support, resuscitation, and hypoalbuminemia. Several biotechnological applications of HSA, including nanoparticles, implantable biomaterials, surgical adhesive and sealants, biochromatography, ligand trapping, and fusion proteins, have been reported.
In this Special Issue, original studies on HSA’s structural, molecular, and functional roles in health and diseases as well as those on the current and future directions of albumin biotechnological applications (e.g., drug delivery and cell culture methodologies) will be warmly welcomed. We welcome original manuscripts, review articles, case reports, and commentaries relating to this hot topic.
Dr. Alessandra Di Masi
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- human serum albumin
- endogenous ligands
- competitive mechanism